|
1
|
Bisig B, Savage KJ and De Leval L:
Pathobiology of nodal peripheral T-cell lymphomas: Current
understanding and future directions. Haematologica. 108:3227–3243.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Weisenburger DD, Savage KJ, Harris NL,
Gascoyne RD, Jaffe ES, MacLennan KA, Rüdiger T, Pileri S, Nakamura
S, Nathwani B, et al: Peripheral T-cell lymphoma, not otherwise
specified: A report of 340 cases from the international peripheral
T-cell lymphoma project. Blood. 117:3402–3408. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zain JM: Aggressive T-cell lymphomas: 2019
Updates on diagnosis, risk stratification, and management. Am J
Hematol. 94:929–946. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fuertes S, Setoain X, Lopez-Guillermo A,
Carrasco JL, Rodríguez S, Rovira J and Pons F: Interim FDG PET/CT
as a prognostic factor in diffuse large B-cell lymphoma. Eur J Nucl
Med Mol Imaging. 40:496–504. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cheson BD, Fisher RI, Barrington SF,
Cavalli F, Schwartz LH, Zucca E, Lister TA; Alliance, Australasian
Leukaemia and Lymphoma Group; Eastern Cooperative Oncology Group;
European Mantle Cell Lymphoma Consortium, ; et al: Recommendations
for initial evaluation, staging, and response assessment of Hodgkin
and non-Hodgkin lymphoma: The Lugano classification. J Clin Oncol.
32:3059–3068. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Vose J, Armitage J and Weisenburger D;
International T-Cell Lymphoma Project, : International peripheral
T-cell and natural killer/T-cell lymphoma study: Pathology findings
and clinical outcomes. J Clin Oncol. 26:4124–4130. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Went P, Agostinelli C, Gallamini A,
Piccaluga PP, Ascani S, Sabattini E, Bacci F, Falini B, Motta T,
Paulli M, et al: Marker expression in peripheral T-cell lymphoma: A
proposed clinical-pathologic prognostic score. J Clin Oncol.
24:2472–2479. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bates SE: Epigenetic therapies for cancer.
N Engl J Med. 383:650–663. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tigu AB and Bancos A: The role of
epigenetic modifier mutations in peripheral T-cell lymphomas. Curr
Issues Mol Biol. 45:8974–8988. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Vallois D, Dobay MP, Morin RD, Lemonnier
F, Missiaglia E, Juilland M, Iwaszkiewicz J, Fataccioli V, Bisig B,
Roberti A, et al: Activating mutations in genes related to TCR
signaling in angioimmunoblastic and other follicular helper
T-cell-derived lymphomas. Blood. 128:1490–1502. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Watatani Y, Sato Y, Miyoshi H, Sakamoto K,
Nishida K, Gion Y, Nagata Y, Shiraishi Y, Chiba K, Tanaka H, et al:
Molecular heterogeneity in peripheral T-cell lymphoma, not
otherwise specified revealed by comprehensive genetic profiling.
Leukemia. 33:2867–2883. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chiba S: Dysregulation of TET2 in
hematologic malignancies. Int J Hematol. 105:17–22. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Muto H, Sakata-Yanagimoto M, Nagae G,
Shiozawa Y, Miyake Y, Yoshida K, Enami T, Kamada Y, Kato T, Uchida
K, et al: Reduced TET2 function leads to T-cell lymphoma with
follicular helper T-cell-like features in mice. Blood Cancer J.
4:e2642014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Solary E, Bernard OA, Tefferi A, Fuks F
and Vainchenker W: The ten-eleven translocation-2 (TET2) gene in
hematopoiesis and hematopoietic diseases. Leukemia. 28:485–496.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yue X, Lio CJ, Samaniego-Castruita D, Li X
and Rao A: Loss of TET2 and TET3 in regulatory T cells unleashes
effector function. Nat Commun. 10:20112019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Haney SL, Upchurch GM, Opavska J,
Klinkebiel D, Hlady RA, Roy S, Dutta S, Datta K and Opavsky R:
Dnmt3a is a haploinsufficient tumor suppressor in CD8+ peripheral T
cell lymphoma. PLoS Genet. 12:e10063342016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dobay MP, Lemonnier F, Missiaglia E,
Bastard C, Vallois D, Jais JP, Scourzic L, Dupuy A, Fataccioli V,
Pujals A, et al: Integrative clinicopathological and molecular
analyses of angioimmunoblastic T-cell lymphoma and other nodal
lymphomas of follicular helper T-cell origin. Haematologica.
102:e148–e151. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Couronné L, Bastard C and Bernard OA: TET2
and DNMT3A mutations in human T-cell lymphoma. N Engl J Med.
366:95–96. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ellin F, Landström J, Jerkeman M and
Relander T: Real-world data on prognostic factors and treatment in
peripheral T-cell lymphomas: A study from the Swedish lymphoma
registry. Blood. 124:1570–1577. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
d'Amore F, Relander T, Lauritzsen GF,
Jantunen E, Hagberg H, Anderson H, Holte H, Österborg A, Merup M,
Brown P, et al: Up-front autologous stem-cell transplantation in
peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 30:3093–3099.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Park SI, Horwitz SM, Foss FM, Pinter-Brown
LC, Carson KR, Rosen ST, Pro B, Hsi ED, Federico M, Gisselbrecht C,
et al: The role of autologous stem cell transplantation in patients
with nodal peripheral T-cell lymphomas in first complete remission:
Report from COMPLETE, a prospective, multicenter cohort study.
Cancer. 125:1507–1517. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mak V, Hamm J, Chhanabhai M, Shenkier T,
Klasa R, Sehn LH, Villa D, Gascoyne RD, Connors JM and Savage KJ:
Survival of patients with peripheral T-cell lymphoma after first
relapse or progression: Spectrum of disease and rare long-term
survivors. J Clin Oncol. 31:1970–1976. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang JY, Briski R, Devata S, Kaminski MS,
Phillips TJ, Mayer TL, Bailey NG and Wilcox RA: Survival following
salvage therapy for primary refractory peripheral T-cell lymphomas
(PTCL). Am J Hematol. 93:394–400. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mead M, Cederleuf H, Björklund M, Wang X,
Relander T, Jerkeman M, Gaut D, Larson S and Ellin F: Impact of
comorbidity in older patients with peripheral T-cell lymphoma: An
international retrospective analysis of 891 patients. Blood Adv.
6:2120–2128. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shi Y, Dong M, Hong X, Zhang W, Feng J,
Zhu J, Yu L, Ke X, Huang H, Shen Z, et al: Results from a
multicenter, open-label, pivotal phase II study of chidamide in
relapsed or refractory peripheral T-cell lymphoma. Ann Oncol.
26:1766–1771. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lemonnier F, Dupuis J, Sujobert P,
Tournillhac O, Cheminant M, Sarkozy C, Pelletier L, Marçais A, Robe
C, Fataccioli V, et al: Treatment with 5-azacytidine induces a
sustained response in patients with angioimmunoblastic T-cell
lymphoma. Blood. 132:2305–2309. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ruan J, Moskowitz A, Mehta-Shah N, Sokol
L, Chen Z, Kotlov N, Nos G, Sorokina M, Maksimov V, Sboner A, et
al: Multicenter phase 2 study of oral azacitidine (CC-486) plus
CHOP as initial treatment for PTCL. Blood. 141:2194–2205.
2023.PubMed/NCBI
|
|
28
|
Falchi L, Ma H, Klein S, Lue JK, Montanari
F, Marchi E, Deng C, Kim HA, Rada A, Jacob AT, et al: Combined oral
5-azacytidine and romidepsin are highly effective in patients with
PTCL: A multicenter phase 2 study. Blood. 137:2161–2170. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Xiao C, Ding Y, Zeng C, Nan Y and Liu Y:
PB2310: Chidamide with azacitidine and chop treatment for patients
with newly diagnosed peripheral T-cell lymphoma: Interim analysis
of a prospective, single center, single-arm, phase 2 trial.
HemaSphere. 7((S3)): e75089382023. View Article : Google Scholar
|
